Fortrea Holdings (FTRE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is FTRE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Fortrea Holdings (FTRE) receives a buy rating due to operational restructuring, improving profitability, and a positive new orders trend despite ongoing revenue decline. FTRE's Q3 2026 results show adjusted EBITDA up 14.…

Fortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execu…

Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript…

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.12 per share a year ago.…

Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth f…

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations…

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Aust…

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Highlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clin…

Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of t…

Ausbil Investment Management Ltd trimmed its position in Fortrea Holdings Inc. (NASDAQ: FTRE) by 25.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang…

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) reached a new 52-week high during trading on Tuesday. The company traded as high as $21.81 and last traded at $22.1050, with a volume of 16613 shares traded. The sto…

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial resul…

Fortrea Holdings Inc. (NASDAQ: FTRE - Get Free Report) has received a consensus rating of "Hold" from the twelve brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell r…

Fortrea (NASDAQ: FTRE - Get Free Report) and Bullfrog AI (NASDAQ: BFRG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strengt…

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock un…

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relation…

Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.…

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth mar…

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

